

July 31 2019

EUR I CLASS

## Fund Information

Fund Name	GuardCap Global Equity Fund
Fund Manager	GuardCap Asset Management Limited
Fund Inception	December 10, 2014
Share Class Inception	October 29, 2015
Share Class	Euro I Class
Style	Growth / Quality Large-Mid Cap. Bottom-Up Fundamental
Legal Status	UCITS
Bloomberg	GCGLEIE
ISIN	IE00BZ036616
WPK	A140FA
Number of Holdings	20-25
Liquidity	Daily at NAV
Annual Management Fee	0.80%
Minimum Investment	\$500,000
Benchmark	MSCI World Index (Net) €

## Fund Statistics

Number of Stocks	25
Net Exposure	97.9%
Fund Size	\$1,077.6 million
Strategy Size	\$2,443.1 million
Active Share	94.8%

## Top 10 Holdings

	Portfolio Weight
Mastercard	8.4%
Alphabet	7.5%
Booking Holdings	6.1%
UnitedHealth Group	5.9%
CME Group	4.9%
EssilorLuxottica	4.9%
Novo Nordisk	4.1%
Ulta Beauty	4.0%
Nestlé	4.0%
Intertek Group	4.0%

## July Contributors / Detractors

	Contribution to Portfolio Return
+ Alphabet	+1.01%
+ Mastercard	+0.44%
+ Moody's	+0.41%
- Illumina	-0.65%
- Novo Nordisk	-0.13%
- Keyence	-0.10%

## Investment Objective

The investment objective of the Fund is to seek long-term growth of capital with lower than market volatility by investing primarily in equity and similar securities issued by high quality companies listed on Recognised Markets in countries which are members of the Organisation for Economic Co-operation and Development ("OECD")

## Investment Process

- Investment philosophy: Growth drives returns; quality protects against downside; valuation matters
- Focused "total immersion" bottom-up analysis of selected "high confidence pool" of stocks
- Concentrated global equity long-only strategy with 20-25 high quality growth investments
- Benchmark agnostic, unconstrained portfolio construction; high active share

## Performance Analysis

	Fund %	Benchmark %	Relative Return %
1 Month	3.35	2.58	0.77
3 Months	3.36	1.74	1.62
YTD	22.95	20.98	1.97
1 Year	14.11	8.99	5.12
Annualised 2 Year	18.35	10.93	7.42
Annualised 3 Year	16.50	10.51	5.99
Annualised Since Inception*	13.77	8.66	5.11

\*EUR I Class Inception date 29/10/15

Past performance results are no indication of future results. Issuance and redemption commissions are not included in the performance figures.

## Discrete Yearly Performance

	Fund %	Benchmark %
31/07/2016 to 31/07/2017	12.87	9.91
31/07/2017 to 31/07/2018	22.76	12.11
31/07/2018 to 31/07/2019	14.11	8.99

\*Inception date 29/10/15 Past performance results are no indication of future results. Issuance and redemption commissions are not included in the performance figures.


## Risk Analysis

Since Inception*	Fund	Benchmark
Tracking Error	4.08	
Standard Deviation	11.19	12.00
Information Ratio	1.63	---
Sharpe Ratio**	1.19	0.55
Upside Market Capture	112.23	100.00
Downside Market Capture	72.40	100.00
Batting Average	0.71	


\* USD I Class

\*\* Risk free rate FTSE 3 month T-bill

## Geographic Allocation (%)



## Sector Allocation (%)



## Manager Commentary

The fund is up 22.95% year-to-date in Euro terms, outperforming the MSCI World Index by 197 basis points. 77 basis points of performance were gained in July. The main contributors in July were **Alphabet, Mastercard** and **Moody's**.

Alphabet rallied on market-beating Q2 2019 results: the company reported a reacceleration of organic revenue growth to over 20% and continues to invest for the next phase of growth from machine learning and AI-powered ads. Moody's ratings business is benefitting from very issuer-friendly market conditions as slowing growth is encouraging central bank action, but also spreads remain tight. Mastercard reported another strong quarter with acceleration across operating metrics and reiterated its full year guidance of low teens organic revenue growth and high teens EPS growth.

The main detractors in July were **Illumina, Novo Nordisk** and **Keyence**.

Illumina sells technology that reads DNA. Genomics is transforming scientific research and medicine. The company cut its full year guidance due primarily to a weaker direct-to-consumer market and the delay of some big contracts. Its competitive position remains very strong – over 90% of all sequencing data has been generated on Illumina technology – and the market opportunity is vast. Novo Nordisk has come under pressure over insulin pricing. While the company needs to get paid for innovation and the list price is never what people pay, it has made investments in co-pay assistance programs, maintains a Patient Assistance Program and ensures a lower priced treatment is available. Keyence, the consulting engineer, reported weaker than expected quarterly results, impacted by a softening demand environment and lower margins due to increased hiring outside Japan and negative operating leverage.

## Portfolio Managers



### Michael Boyd | Investment Manager

Michael has been managing fundamental equity funds for over 25 years. He joined GuardCap in June 2014. From 1994 to 2013, Michael was at the London-based institutional fund management company, Seilern Investment Management Ltd., as global equity fund manager, Managing Director and shareholder. From 1988 to 1994 he was a fund manager at Murray Johnstone Limited in Glasgow. He received an honours degree in economics from Heriot-Watt University, Edinburgh and qualified as an Associate of the Institute of Bankers in Scotland.



### Giles Warren | Investment Manager

Giles joined GuardCap in August 2014. Prior to this, he worked with Michael Boyd on the Seilern Stryx World Growth Fund from 1997, becoming joint fund manager of that fund in 2010. He graduated from Edinburgh University with an honours degree in politics and economic history. He is an Associate of the Society of Investment Professionals.

## For More Information:

Michael Hughes  
 mhughes@guardiancapital.com | +44-20-7907-2405

Alexandra Schwarz  
 aschwarz@guardiancapital.com | +44-20-7907-2011

**Disclaimer:** Issued by GuardCap Asset Management Limited which is authorised and regulated by the Financial Conduct Authority. This document includes information concerning financial markets that was developed at a particular point in time and is subject to change at any time, without notice, and without update. This document may also include forward looking statements concerning anticipated results, circumstances, and expectations regarding future events. Forward-looking statements require assumptions to be made and are, therefore, subject to inherent risks and uncertainties. There is significant risk that predictions and other forward looking statements will not prove to be accurate. Investing involves risk. Equity markets are volatile and will increase and decrease in response to economic, political, regulatory and other developments. Investment funds are not guaranteed, their values change frequently and past performance is not a reliable indicator of future results. This information is for general information purposes only and is not intended as legal, tax, accounting, securities, or investment advice. This information is not intended for distribution into any jurisdiction where such distribution is restricted by law or regulation. It shall under no circumstances be considered an offer or solicitation to deal in any product mentioned herein. GuardCap Asset Management Limited is the Manager of the Fund and an indirect, wholly-owned subsidiary of Guardian Capital Group Limited, a publicly traded firm listed on the Toronto Stock Exchange. For further information on GuardCap Asset Management Limited, or this Fund please visit [www.guardcap.co.uk](http://www.guardcap.co.uk) to view the Prospectus, KIID and other relevant documents.

**Note to Swiss Investors Only:** This is marketing information. Investment in investment funds is subject to market risks. Past performance results are no indication of future results. Especially performance results referring to a period of less than twelve months are no reliable indicator for future results due to the short comparison period. Issuance and redemption commissions are not included in the performance figures. The domicile of the Fund is Ireland. For interested parties, the prospectus, the Key Investor Information Documents (KIIDs), the memorandum of articles as well as the annual and semi-annual reports may be obtained free of charge from the Swiss representative and paying agent in Switzerland: RBC Investor Services Bank S.A., Esch-sur-Alzette, Zurich Branch, Bleicherweg 7, CH-8027 Zurich.